文献速递乳腺癌

新辅助DTP方案对比T-DM1单药治疗ERBB2阳性乳腺癌的2期随机试验

Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2021-01-01

这项在瑞典9个中心开展的2期随机试验纳入202例ERBB2阳性乳腺癌患者,比较6周期多西他赛+曲妥珠单抗+帕妥珠单抗(DTP)与T-DM1单药的病理完全缓解(pCR)。DTP组pCR为45.5%,T-DM1组为43.9%,差异无统计学意义(P=.82)。

要点

  • 标准新辅助DTP方案与T-DM1单药在pCR上疗效相当。
  • 激素受体阴性者pCR率高于阳性者(62.5% vs 36.0%)。
  • 肿瘤浸润淋巴细胞≥10%及PET-CT代谢下降与pCR相关。

核心结论

  • 标准新辅助DTP方案与T-DM1单药治疗的pCR率无显著差异,DTP不劣于T-DM1。

研究设计与样本

  • 随机2期试验,在瑞典9个中心开展,2014年12月1日至2018年10月31日入组202例患者,按意向治疗分析。
  • 入组标准为18岁及以上、ERBB2阳性肿瘤大于20 mm和/或淋巴结转移证实。
  • 患者随机接受6周期DTP(标准组)或T-DM1(研究组),无缓解或不耐受毒性时推荐交叉。

主要发现

  • 标准组pCR为45.5%(95%CI 35.4%-55.8%),研究组为43.9%(95%CI 33.9%-54.3%),差异无统计学意义(P=.82)。
  • 激素受体阴性肿瘤pCR率高于阳性肿瘤(45/72[62.5%] vs 45/125[36.0%])。
  • T-DM1组有3例患者在治疗期间出现疾病进展。
  • 探索性分析显示肿瘤浸润淋巴细胞≥10%(中位数)与pCR显著相关(OR 2.76;95%CI 1.42-5.36;P=.003)。
  • 18F-FDG PET-CT显示最大标准化摄取值相对下降≥68.7%(中位数)与pCR相关(OR 6.74;95%CI 2.75-16.51;P<.001)。

临床怎么用

  • 对于ERBB2阳性乳腺癌新辅助治疗,DTP联合方案与T-DM1单药均可作为选择,需结合毒性及生物标志物个体化决策。
  • 激素受体状态、肿瘤浸润淋巴细胞水平及PET-CT代谢反应可用于辅助预测pCR。

局限性

  • 本研究为2期随机试验,样本量有限,结果需更大规模3期试验验证。
  • 原文未报告总生存、无事件生存等长期结局的详细数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Trastuzumab emtansine (T-DM1) is presently approved for treatment of advanced breast cancer and after incomplete response to neoadjuvant therapy, but the potential of T-DM1 as monotherapy is so far unknown. OBJECTIVE: To assess pathologic complete response (pCR) to standard neoadjuvant therapy of combination docetaxel, trastuzumab, and pertuzumab (DTP) vs T-DM1 monotherapy in patients with ERBB2 (formerly HER2)-positive breast cancer. DESIGN, SETTING, AND PARTICIPANTS: This randomized phase 2 trial, conducted at 9 sites in Sweden, enrolled 202 patients between December 1, 2014, and October 31, 2018. Participants were 18 years or older, with ERBB2-positive tumors larger than 20 mm and/or verified lymph node metastases. Analysis was performed on an intention-to-treat basis. INTERVENTIONS: Patients were randomized to receive 6 cycles of DTP (standard group) or T-DM1 (investigational group). Crossover was recommended at lack of response or occurrence of intolerable toxic effects. Assessment with fluorine 18-labeled fluorodeoxyglucose (18F-FDG) positron emission tomography combined with computed tomography (PET-CT) was performed at baseline and after 2 and 6 treatment cycles. MAIN OUTCOME AND MEASURES: Pathologic complete response, defined as ypT0 or Tis ypN0. Secondary end points were clinical and radiologic objective response; event-free survival, invasive disease-free survival, distant disease-free survival, and overall survival; safety; health-related quality of life (HRQoL); functional and biological tumor characteristics; and frequency of breast-conserving surgery. RESULTS: Overall, 202 patients were randomized; 197 (99 women in the standard group [median age, 51 years (range, 26-73 years)] and 98 women in the investigational group [median age, 53 years (range, 28-74 years)]) were evaluable for the primary end point. Pathologic complete response was achieved in 45 patients in the standard group (45.5%; 95% CI 35.4%-55.8%) and 43 patients in the investigational group (43.9%; 95% CI 33.9%-54.3%). The difference was not statistically significant (P = .82). In a subgroup analysis, the pCR rate was higher in hormone receptor-negative tumors than in hormone receptor-positive tumors in both treatment groups (45 of 72 [62.5%] vs 45 of 125 [36.0%]). Three patients in the T-DM1 group experienced progression during therapy. In an exploratory analysis, tumor-infiltrating lymphocytes at 10% or more (median) estimated pCR significantly (odds ratio, 2.76; 95% CI, 1.42-5.36; P = .003). Response evaluation with 18F-FDG PET-CT revealed a relative decrease of maximum standardized uptake value by equal to or greater than 68.7% (median) was associated with pCR (odds ratio, 6.74, 95% CI, 2.75-16.51; P < .001). CONCLUSIONS AND RELEVANCE: In this study, treatment with standard neoadjuvant combination DTP was equal to T-DM1. TRIAL REGISTRATIONS: ClinicalTrials.gov Identifier: NCT02568839; EudraCT number: 2014-000808-10.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Hatschek T, Foukakis T, Bjöhle J, et al. Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 34165503. doi:10.1001/jamaoncol.2021.1932

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。